Selected outcome
a full approval or an accelerated approval
96%
a full approval or an accelerated approval · 96%
Stored quote · checking the venue
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- AppliedXL (opens in a new tab)
Price
a full approval or an accelerated approval
Loading price history.
Markets
- a full approval or an accelerated approval
What will the FDA's decision be on Bepirovirsen by GlaxoSmithKline in 2026?
96%
Open · ~$0 24h · ~$3,808 vol
Bid 92¢ · Ask 99¢
Event statistics
How this resolves
One winner.
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- Trading
- Closed
- In review
- Resolved
Rules text
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.